Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Triplet vs Doublet Therapy for mCSPC

October 25th 2019

Prostate Cancer: Characterize Biologies, Integrate Therapies

October 25th 2019

STAMPEDE: Docetaxel for Hormone-Naive Prostate Cancer

October 25th 2019

Clinical Phenotypes of Prostate Cancer and Prognostic Factors

October 25th 2019

Prostate Cancer: PSA-DT and Initiating AR-Targeted Therapy

October 25th 2019

QOL in Nonmetastatic Castration-Resistant Prostate Cancer

October 25th 2019

ARAMIS: Safety and Efficacy of Darolutamide in nmCRPC

October 25th 2019

Nonmetastatic Castration-Resistant Prostate Cancer

October 25th 2019

Early Salvage Radiotherapy for Early Prostate Cancer

October 25th 2019

Active Surveillance and Prognostic Value of Prostate Biopsy

October 25th 2019

Optimal ADT for Patients With Prostate Cancer and CV History

October 25th 2019

Combination Therapy for Localized Prostate Cancer

October 25th 2019

ADT and Its Consequences in the Treatment of Prostate Cancer

October 25th 2019

Dr. Bryce on Treatment Selection in Nonmetastatic Castration-Resistant Prostate Cancer

October 25th 2019

Alan H. Bryce, MD, discusses treatment selection in nonmetastatic castration-resistant prostate cancer.

Dr. de Wit on Rationale for Phase III CARD Trial in Metastatic CRPC

October 24th 2019

Ronald de Wit, MD, PhD, discusses the rationale for the randomized phase III CARD trial which showed a significant overall survival benefit with third-line cabazitaxel in patients with metastatic castration-resistant prostate cancer.

Dr. Giri on the PROGRESS Registry for Genetic Testing in Prostate Cancer

October 24th 2019

Veda N. Giri, MD, discusses the PROGRESS registry in genetic testing and counseling for prostate cancer.

Apalutamide Preserves HRQoL in Metastatic Castration-Sensitive Prostate Cancer

October 23rd 2019

Neeraj Agarwal, MD, discusses the TITAN trial and the implications in prostate cancer treatment.

Dr. George on the Changing Treatment Landscape in Prostate Cancer

October 23rd 2019

Daniel J. George, MD, discusses the changing treatment landscape in prostate cancer.

Coupling Novel Approaches With Chemo in Advanced Prostate Cancer

October 23rd 2019

Daniel J. George, MD, discusses staples of treatment in metastatic prostate cancer as well as novel therapies and emerging strategies in the field.

Dr. Pettaway on Importance of Inclusive Germline Testing in Prostate Cancer

October 22nd 2019

Curtis A. Pettaway, MD, discusses the need to include the genomic data of African American, Asian, and Hispanic men with prostate cancer in national registries.